Key result
Review summarizes current evidence on leadless pacemakers for cardioinhibitory vasovagal syncope.
Why the study?
A subset of patients with severe cardioinhibitory vasovagal syncope may benefit from permanent pacing, and leadless pacemaker systems mitigate many risks of traditional transvenous pacemakers.
Do leadless pacemaker systems benefit patients with cardioinhibitory vasovagal syncope?
Do leadless pacemaker systems benefit patients with cardioinhibitory vasovagal syncope?
This review summarizes available data on using leadless pacemakers to treat cardioinhibitory vasovagal syncope, highlighting their potential to mitigate risks associated with traditional transvenous systems.
Leadless pacemakers may reduce transvenous risks in cardioinhibitory vasovagal syncope; leaves open need for randomized efficacy trials.
Vasovagal syncope (VVS) is largely a benign condition focused on patient education, lifestyle modification, and avoidance of triggers. However, a subset of patients may benefit from permanent pacemaker placement. Commonly, patients with VVS are younger and those requiring pacing have symptoms associated with severe cardioinhibitory syncope. With the advent of leadless pacemaker systems, a lot of the risks associated with traditional transvenous pacemaker systems are mitigated. In this article, we provide a comprehensive review of the data available for the treatment of cardioinhibitory vasovagal syncope using leadless pacemaker systems.
No takes yet. Share an insight, caveat, or question.
Kadado et al. (2023) conducted a review in Cardioinhibitory vasovagal syncope. Leadless pacemaker systems was evaluated. This comprehensive review summarizes the available data on the use of leadless pacemaker systems for the treatment of cardioinhibitory vasovagal syncope.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: